Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

View Full Paper
Ask AI
Bookmark
Share

Authors

JFJingjing FengXFXintong FengSFShan Fu

Discussion

Loading...

Member takes

Overview

Observational analysis improved remission rates in refractory systemic lupus erythematosus, suggesting immunotherapy's role in treatment.

Key Points

  • GC012F therapy improved remission rates in patients with refractory SLE, leading to sustained DORIS and LLDAS outcomes.
  • By one-year post-infusion, 60% of participants achieved DORIS remission, with significant reductions in serological autoantibody levels.
  • Open-label study involved 15 patients receiving a single GC012F infusion, showing full B cell depletion and immune reset potential.
  • The findings highlight the need for further evaluation of this dual-targeting approach in larger SLE cohorts.

Cite This Study

Feng et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236ddbbhttps://doi.org/10.1182/blood-2025-2384
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and preliminary efficacy of a novel loop-optimized, BCMA/CD19 bispecific CAR-T therapy for refractory or relapsed autoimmune diseases patients2025
  2. 2A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma2025 · 3 citations
  3. 3BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial2025 · 1 citations
  4. 4Rapid normalization of platelet counts in patients with refractory thrombocytopenia associated with systemic lupus erythematosus (SLE) following treatment with allogeneic dual-target CD19/BCMA CAR T-cell therapy (QT-019B)2025
  5. 5Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study2025 · 9 citations